<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>79</patient-age><report-id>PHHY2012MX113572</report-id><gender>male</gender><reactions><reaction>Respiratory arrest</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>EXELON PATCH</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Dementia Alzheimer's type</indication></indications><patient-age>79</patient-age><outcomes><outcome>Death</outcome></outcomes><country>Mexico</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053225_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134652</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012MX113572</safetyreportid>
		<primarysourcecountry>MX</primarysourcecountry>
		<occurcountry>MX</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>1</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-09</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-09</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012MX113572</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>MX</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>79</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hepatic cirrhosis</patientepisodename>
			</medicalhistoryepisode>
			<patientdeath>
				<patientdeathdateformat>102</patientdeathdateformat>
				<patientdeathdate>20121024</patientdeathdate>
				<patientautopsyyesno>3</patientautopsyyesno>
				<patientdeathcause>
					<patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
					<patientdeathreport>Respiratory arrest</patientdeathreport>
				</patientdeathcause>
			</patientdeath>
			<reaction>
				<primarysourcereaction>Respiratory arrest</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Respiratory arrest</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Respiratory arrest</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121024</reactionstartdate>
				<reactionoutcome code="5">fatal</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>EXELON PATCH</medicinalproduct>
				<obtaindrugcountry>MX</obtaindrugcountry>
				<drugauthorizationnumb>22-083</drugauthorizationnumb>
				<drugauthorizationcountry>MX</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>4.6</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>4.6 mg/5 cm2 one patch daily</drugdosagetext>
				<drugdosageform normalized="trans-therapeutic-system">Trans-therapeutic-system</drugdosageform>
				<drugadministrationroute code="062">Transdermal</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Dementia Alzheimer's type</drugindication>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2012-10-01</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>RIVASTIGMINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Respiratory arrest</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Respiratory arrest</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012MX113572 is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from a consumer (patient's daughter) on 09 Dec 2012: This report refers to a 79-year old male patient. Medical history included <Semaphore x="1783138" class="Disease or Finding" value="Cirrhosis" score="1.00" ID="C2951">cirrhosis</Semaphore>. The patient received <Semaphore x="560518" class="Medicine" value="Exelon" score="0.49" ID="249270">Exelon </Semaphore>patch (<Semaphore x="1142851" class="Medicine" value="rivastigmine" score="0.49" ID="239962">rivastigmine</Semaphore>) 4.6 mg/5 cm2 one patch daily since Oct 2012 for <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="1478175" class="Disease or Finding" value="Alzheimer's Disease" score="1.00" ID="C2866">Alzheimer's disease</Semaphore>. On 24 Oct 2012, the patient experienced <Semaphore x="2463617" class="Disease or Finding" value="Respiratory Arrest" score="1.00" ID="C101772">respiratory arrest</Semaphore>. On 24 Oct 2012, the patient died due to <Semaphore x="2463617" class="Disease or Finding" value="Respiratory Arrest" score="1.00" ID="C101772">respiratory arrest</Semaphore>. The causality <Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">assessment </Semaphore>was not reported.</narrativeincludeclinical>
				<sendercomment>Medical assessment comment: Review of available reported data does not allow for a proper causality assessment. </sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>